Best wishes 2023
Advancing cancer therapies. At the speed of light

Advancing cancer therapies. At the speed of light.

Hemerion® develops a unique and disruptive technology to treat glioblastoma.
A breakthrough therapy for glioblastoma patients

A breakthrough therapy for glioblastoma patients

Promising early clinical results

Promising early clinical results

A disruptive technology to tackle brain cancer and glioblastoma


Prof. Costas Hadjipanayis joins Pittsburg

Prof. Costas Hadjipanayis named head of the University of Pittsburgh (UPMC) Image-Guided Neurosurgery Center

December 19, 2022

Professor Costas Hadjipanayis, a member of Hemerion's Scientific Advisory Board, has been appointed head of several neurosurgery centers at the University of Pittsburgh in the USA. An active member of… ...

Read more

Maximilien Vermandel at the inauguration of Hemerion's new premises

Hemerion continues to grow and inaugurates its new premises

October 20, 2022

Two years after its launch, Hemerion Therapeutics inaugurated its new premises on Thursday, October 20. Located in Villeneuve d’Ascq in the North of France, Hemerion Headquarters houses the team in… ...

Read more

Prof. Costas Hadjipanayis and Maximilien Vermandel

Mission to New York: Phase II clinical trials progress and Heliance successfully tested

July 12, 2022

A new mission organized by Hemerion in the United States enabled us to test the new version of the Heliance laser diffuser and to specify the outlines of the phase… ...

Read more

mail icon

Stay tuned to our clinical advances

Subscribe to our newsletter

They talk about us